"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand Shares of Eli Lilly & Co. are rising in premarket trading after the pharmaceutical giant raised its full-year revenue forecast following a 48% jump in second-quarter sales, fueled by accelerating demand for the diabetes drug Mounjaro and the obesity treatment Zepbound. Lilly's second-quarter results topped Wall Street expectations: Adjusted earnings rose to $8.38 a share from $6.31 a year earlier. Revenue surged 48% to $22.97 billion, beating the $20.59 billion Bloomberg Consensus estimate. Mounjaro generated $9.94 billion in sales, exceeding the $8.83 billion estimate, while Zepbound revenue climbed 18% from the previous quarter to $4.93...
Read the full article at the source.
Comments (0)
No comments yet. Be the first to comment!